Ben Haynor: Okay. So — and there wasn’t any kind of 1x-ish G&A expenses associated with the deal?
Richard Brounstein: No, not in the quarter, no. I mean, anything that was associated with the financing is all just ran through stockholders’ equity, didn’t go to the P&L.
Ben Haynor: Okay, got it. And then on the cost reduction program, with Triple Ring, how’s that progressing? Any more color there that you can provide? That’s it for me.
Richard Brounstein: Hey, Branislav, do you want to handle that one, or?
Branislav Vajdic: Go ahead, Rick.
Richard Brounstein: Yes. Okay. So, Ben, I mean, it’s probably going to be most of the year. We’re doing things to take basically a prototype-level device that costs over $1,000 and reduces to something that, when we start to get in volumes, will be a couple of $100, right? So, there’s various pieces that are going on. It’s ongoing. We’re looking at the PCB board. We’re looking at some molds that we’ll buy and some other things. But it’s a dedicated approach now that we look forward to commercialization to be able to produce, if you would, the credit card at a reasonable price.
Operator: [Operator Instructions] At this time, we will now take questions from our webcast.
Unidentified Company Representative: Our first question asks, you mentioned that you have withdrawn AIMI. Can you tell me more about that decision?
Branislav Vajdic: Let me handle that question. Our strategic focus is on ambulatory devices. You know, AIMI application by Valuable had a very different market and distribution strategy. As we have seen the opportunity with our AIMIGo ambulatory VECG device and as we make progress and get closer to its market availability, it is important for us to totally focus and take advantage of that huge opportunity. This market is a much larger market, probably 20x or more than that of the emergency room market. The great need and the key opportunity is to bring the 12-Lead VECG to the patient outside of the healthcare institution. Actually, the algorithm that we developed for AIMI which basically takes the 12-Lead VECG and converts it to the VECG and runs analysis on the VECG is planned to be included in the future generations of AIMIGo as well. So in that sense, we expect to see this technology appear in AIMIGo down the line.
Unidentified Company Representative: Our second and final webcast question is, you are providing only high-level details on the timings of the future FDA submissions and clearances rather than a detailed timeline. You say you’re expecting a limited market release in the second half of 2024. Can you provide more context?
Branislav Vajdic: Yes, Rob, would you please go ahead?
Robert Eno: Sure. Yes, the one thing that’s clear about regulatory filings and the whole regulatory process is the timing’s uncertain. And to a large extent, it’s outside of our control when dealing with regulatory agencies. So we’re going to continue to update on our progress toward our milestones, things that we’ve achieved as we did today, talking both about the version 1 and version 2 products. But rather than give estimates on the timing of some of these upcoming intermediate steps, we decided to focus on the key milestone which is this limited market release of AIMIGo which happens after the clearance of version 2 in the second half of 2024. And we’ll continue to do that going forward is focus on that ultimate date of market release but also keep providing updates on the progress and the milestones that we’ve achieved.
Operator: I would now like to turn the floor back over to Dr. Vajdic for his closing comments.
Branislav Vajdic: Thank you, operator. I would like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If you were unable to answer any of your questions, please reach out to IR firm, MZ Group, who would be more than happy to assist. Thank you again.
Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.
